Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Azumah Resources appoints two new directors to board

2018-07-17 proactiveinvestors.com.au
Azumah Resources Ltd (ASX:AZM) will replace the outgoing Geoff Jones with two new board appointments aimed at supporting development and financing of the Wa Gold Project in Ghana.
AZUMF AZM

0
Azumah Resources delivers proof of concept for feeder zone at Wa Gold Project

2018-07-03 proactiveinvestors.com.au
Azumah Resources Limited (ASX:AZM) is continuing to progress its exploration campaigns on multiple fronts at the Wa Gold Project in Ghana aimed at updating the resource and delivering an interim ore reserve.
AZUMF AZM

0
Azumah Resources shares soar following "major step forward"

2018-05-08 proactiveinvestors.com.au
Azumah Resources Ltd (ASX:AZM) managing director Steve Stone talks Proactive Investors through fresh RC drilling results from the gold prospector's Wa Project in Ghana under JV with Ibaera.
AZUMF AZM

0
Azumah Resources delivers game-changing gold intersections from Wa project in Ghana

2018-05-08 proactiveinvestors.com.au
Azumah Resources Ltd (ASX:AZM) has delivered potentially game-changing intersections at the Kunche from the Wa Gold Project in Ghana.
AZUMF AZM

0
Azumah Resources enters trading halt pending exploration results from Ghana

2018-05-07 proactiveinvestors.com.au
Azumah Resources Limited (ASX:AZM) has entered an ASX trading halt pending the release of an update regarding material exploration results from drilling at the Wa Gold Project in Ghana.
AZUMF AZM

0
Azumah Resource secures $1.5 million on road to one million ounce ore reserve

2018-04-24 proactiveinvestors.com.au
Azumah Resources Ltd (ASX:AZM) has received commitments to raise $1.5 million in a share placement priced at 2.2 cents per share.
AZUMF AZM

4
Azumah Resources poised to expand 2.1 million ounce gold bounty and transition to producer

2018-04-20 proactiveinvestors.com.au
Azumah Resources Limited (ASX:AZM) appears substantially undervalued compared with other gold explorers and developers on an enterprise value to resource ounce basis.
FSUMF AZUMF FMG AZM FSUGY

0
Azumah Resources flags capital raising as it looks to grow reserves at gold project in Ghana

2018-04-20 proactiveinvestors.com.au
Azumah Resources Limited (ASX:AZM), owner of the Wa Gold Project, has entered a trading halt ahead of releasing details regarding a capital raising.
AZUMF AZM

0
Azumah Resources reaffirms gold drilling success at Butele North target in Ghana

2018-03-21 proactiveinvestors.com.au
Azumah Resources Ltd (ASX:AZM) has revealed a cross-section of its first-pass drilling result of 16 metres at 1.07 g/t gold from surface (including 6 metres at 1.86 g/t gold) at the Butele North target.
AZUMF AZM

0
Azumah Resources hits gold at new Butele North target in Ghana

2018-03-18 proactiveinvestors.com.au
Azumah Resources Ltd (ASX:AZM) has drilled out gold in its first pass drill program at the Butele North target within the Wa Gold Project in Ghana.
AZUMF AZM

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

3h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AZM / AZUMAH RESOURCES LIMITED on message board site Silicon Investor.

AZM Tazmanu0027s Bulletin Board Bulletin (TBBB)